Search research articles
Contact Us
Filters
Showing results (41-50 of 198) with videos related to
Page
of 20
Sort By:
Rheumatology and Therapy
|
February 27, 2023
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Vivian P Bykerk, Peter Nash, David Nicholls, et al.
BJU International
|
October 22, 2015
Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series
Rasha Gendy, Warick Delprado, Phillip Brenner, et al.
RMD Open
|
September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Therapeutic Advances in Musculoskeletal Disease
|
August 30, 2023
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Atul Deodhar, Dafna Gladman, Rebecca Bolce, et al.
Rheumatology Advances in Practice
|
April 17, 2025
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis
Dafna D Gladman, Maxime Dougados, Helena Marzo-Ortega, et al.
Rheumatology and Therapy
|
October 18, 2016
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash, Johan Vanhoof, Stephen Hall, et al.
RMD Open
|
January 21, 2020
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Dafna Gladman, Peter Nash, Hitoshi Goto, et al.
The Journal of Rheumatology
|
November 1, 2022
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Ennio Lubrano, Jon Chan, Ruben Queiro-Silva, et al.
Arthritis Research & Therapy
|
December 20, 2024
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Dafna D Gladman, Peter Nash, Philip J Mease, et al.
Clinical and Experimental Rheumatology
|
August 2, 2022
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study
Bruce Kirkham, Peter Nash, Delia Reina, et al.
Page
of 20
Search research articles
Search
Showing results (41-50 of 198) with videos related to
Sort By:
Page
of 20
Rheumatology and Therapy
|
February 27, 2023
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Vivian P Bykerk, Peter Nash, David Nicholls, et al.
BJU International
|
October 22, 2015
Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series
Rasha Gendy, Warick Delprado, Phillip Brenner, et al.
RMD Open
|
September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Therapeutic Advances in Musculoskeletal Disease
|
August 30, 2023
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Atul Deodhar, Dafna Gladman, Rebecca Bolce, et al.
Rheumatology Advances in Practice
|
April 17, 2025
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis
Dafna D Gladman, Maxime Dougados, Helena Marzo-Ortega, et al.
Rheumatology and Therapy
|
October 18, 2016
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash, Johan Vanhoof, Stephen Hall, et al.
RMD Open
|
January 21, 2020
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Dafna Gladman, Peter Nash, Hitoshi Goto, et al.
The Journal of Rheumatology
|
November 1, 2022
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Ennio Lubrano, Jon Chan, Ruben Queiro-Silva, et al.
Arthritis Research & Therapy
|
December 20, 2024
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Dafna D Gladman, Peter Nash, Philip J Mease, et al.
Clinical and Experimental Rheumatology
|
August 2, 2022
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study
Bruce Kirkham, Peter Nash, Delia Reina, et al.
Page
of 20